Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 16/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165226 | 0.88 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL15459955 | 0.81 | HSD11B1 (0.53) | HSD11B1TSHRPDK1PDK2PDK3 | |
| SCHEMBL25753451 | 0.81 | HSD11B1 (0.53) | HSD11B1 | |
| Phenaglycodol SCHEMBL329242 | 0.81 | MEN1 (0.65) | MEN1KMT2AHSD11B1TSHRMAPK1 | |
| SCHEMBL29091899 | 0.81 | MEN1 (0.65) | MEN1KMT2AHSD11B1TSHRMAPK1 | |
| SCHEMBL29091903 | 0.81 | MEN1 (0.65) | MEN1KMT2AHSD11B1TSHRMAPK1 | |
| Phenaglycodol SCHEMBL259155 | 0.81 | MEN1 (0.65) | MEN1KMT2AHSD11B1TSHRMAPK1 | |
| SCHEMBL29092067 | 0.81 | MEN1 (0.65) | MEN1KMT2AHSD11B1TSHRMAPK1 | |
| SCHEMBL31507653 | 0.79 | KMT2A (0.52) | MEN1KMT2AHSD11B1TSHRMAPK1 | |
| SCHEMBL14697375 | 0.79 | HSD11B1 (0.72) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022130403-A1 | NEW QUATERNARY AMMONIUM SALTS FOR TRIFLUOROMETHYLATION AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-06-23 | — | — | WO | claimed |
| US-11785845-B2 | Composition | FUJIFILM CORPORATION (JP) | 2023-10-10 | — | — | US | disclosed |
| WO-2022130403-A1 | NEW QUATERNARY AMMONIUM SALTS FOR TRIFLUOROMETHYLATION AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-06-23 | — | — | WO | disclosed |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | KANTO DENKA KOGYO CO., LTD. (JP) | 2019-10-22 | — | — | US | disclosed |
| EP-3495341-A1 | METHOD FOR PRODUCING PERFLUOROALKYL COMPOUND USING MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | Kanto Denka Kogyo Co., Ltd. (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2019-06-06 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2011073487-A1 | PROCEDURE FOR THE ENANTIOSELECTIVE ADDITION OF ORGANOZINC COMPOUNDS TO COMPOUNDS DERIVED FROM ACETOPHENONES | UNIVERSIDAD DE VALLADOLID (ES) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11785845-B2 | Composition | ADH1A, ADH1C, SLC19A2 | MEN1 740/4885KMT2A 1344/4885HSD11B1 119/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | MEN1 4072/4885KMT2A 3843/4885HSD11B1 1443/4885 |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | PFKFB1, PFKFB4, PFAS | MEN1 1558/4885KMT2A 543/4885HSD11B1 149/4885 |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | PFKFB1, PFKFB4, PFAS | MEN1 1558/4885KMT2A 543/4885HSD11B1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.